Trial Profile
COVID-19 (CoviCompareCV): A Phase 3, Non-randomized, Open Label Clinical Trial to Evaluate the Immunogenicity and Safety of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Adults Aged 65 Years or Above Compared to Younger Adults Aged 18-45 Years
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors CureVac
- 16 Aug 2021 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 16 Aug 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Jan 2022.
- 16 Aug 2021 Planned initiation date changed from 14 May 2021 to 1 Oct 2021.